Navigation Links
Interleukin Genetics to Raise $5.3 Million in Registered Direct Offering

WALTHAM, Mass., March 5 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) today announced that it has received commitments from certain institutional investors to purchase approximately $5.3 million of securities in a registered direct offering.  The Company expects to receive net proceeds of approximately $4.9 million after deducting placement agent fees and other offering expenses.  Interleukin Genetics has entered into securities purchase agreements with these investors pursuant to which Interleukin Genetics has agreed to sell an aggregate of 4,375,002 shares of its common stock and warrants to purchase up to 1,750,000 additional shares of common stock.  Each unit, consisting of one share of common stock and a warrant to purchase 0.40 of a share of common stock, will be sold for a purchase price of $1.20.

The warrants will be exercisable at an exercise price of $1.30 per share beginning immediately after issuance and will expire 5 years from the date they are first exercisable.  All of the securities were offered pursuant to an effective shelf registration statement. The offering is expected to be consummated by March 10, 2010, subject to customary closing conditions.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc., (Nasdaq: RODM), acted as the exclusive placement agent for the transaction.

A shelf registration statement relating to the shares of common stock and warrants issued in the offering (and shares of common stock issuable upon exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC") and has been declared effective.  A prospectus supplement relating to the offering will be filed by Interleukin Genetics with the SEC.  Copies of the prospectus supplement and accompanying prospectus may be obtained directly from Interleukin Genetics by contacting the company at 135 Beaver Street, Waltham, Massachusetts 02452 or via Telephone at (781) 398-0700 or via email at  This announcement is neither an offer to sell nor a solicitation of an offer to buy any common stock or warrants of Interleukin Genetics.  No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI) develops and markets genetic tests that empower consumers to prevent certain chronic diseases and that assist pharmaceutical companies in the development and marketing of targeted therapeutics. The Company leverages its research, intellectual property and biomarker development experience to facilitate the emerging personalized health market. Interleukin Genetics markets a line of genetic tests under the Inherent Health brand including Bone Health, Weight Management, Heart Health and Nutritional Needs.  The Company is headquartered in Waltham, MA. 

Certain statements contained herein are "forward-looking" statements, including statements regarding the expected timing of consummation of the offering.  Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company's  annual report on Form 10-K for the year ended December 31, 2008, quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.

SOURCE Interleukin Genetics, Inc.; Rodman & Renshaw, LLC

Back to top



SOURCE Interleukin Genetics, Inc.; Rodman & Renshaw, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis
2. Interleukin Genetics, Inc. Announces Positive Results from Clinical Study Evaluating Genetic Tests Impact on Weight Loss
3. Interleukin Genetics Presents Research Linking Vertebral Fractures to Gene Variations in Asian Women With Osteoporosis
4. Interleukin Genetics and Geisinger to Collaborate on Genetic Tests to Predict Weight Loss Success
5. Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis
6. Interleukin Genetics Wins International Award for Outstanding Research Published in the Journal, Nutrition
7. Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
11. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
Post Your Comments:
(Date:11/30/2015)... CHICAGO , Nov. 30, 2015   Nuance ... The National Decision Support Company (NDSC) today ... support and collaboration capabilities that utilize the American College ... and healthcare provider organizations to comply with current ... --> --> By combining clinical ...
(Date:11/30/2015)... Nov. 30, 2015 Booth #4303 – The Imaging ... will exhibit a broader array of products in a new ... of North America in ... meeting will feature X-ray components "At the Heart of Imaging." ... of products from Varian,s Claymount brand, and computer-aided diagnostic software ...
(Date:11/30/2015)... -- Hanger, Inc. (NYSE: HGR ) (the "Company") today ... its previously announced consent solicitation (as amended and restated, ... amount 7⅛% Senior Notes due 2018 (the "Notes") to ... pursuant to the Consent Solicitation, (ii) the proposed increased ... date of the Consent Solicitation.    ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... last 15 years, announced today that Michigan-based Family Health Center (FHC) has selected ... over 45 years, FHC was awarded the largest Affordable Care Act grant for ...
(Date:11/30/2015)... Ill. (PRWEB) , ... November 30, 2015 , ... ... Decision Support Solutions, announced at the Radiology Society of North America (RSNA) annual ... have seen over 60% growth from 2014. Throughout 2015, the company has ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... publishing magazines and websites specializing in independent living, assisted living and all other ... and Alzheimer’s awareness and research remains a top priority. , ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... is pleased to announce the speakers for “Value-Based Payer-Provider Partnerships: Three Case ... from three innovative value-based care arrangements: Essentia Health and UCare, MissionPoint Health ...
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... ... software provider, has verified that their Vasont Universal Integrator (VUI) extension unites with ... creating, editing, and managing content as a continuous process with the latest release ...
Breaking Medicine News(10 mins):